| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/23/2002 | CN1331992A Chinese herbal medicine for treating hypertension |
| 01/23/2002 | CN1331989A Chinese medicine for treating thromboangitis obliterans |
| 01/23/2002 | CN1331971A New use of deferketoamine |
| 01/22/2002 | US6340752 Cleavage of thio group from carbonyl and conversion to lactam ester |
| 01/22/2002 | US6340700 2-(iminomethyl) amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same |
| 01/22/2002 | US6340685 Antiinflammatory agents |
| 01/22/2002 | US6340681 Useful as analgesics in mammals |
| 01/22/2002 | US6340679 Guanidine derivatives as inhibitors of cell adhesion |
| 01/22/2002 | CA2259962C Therapeutic applications of t-bam (cd40l) technology to treat diseases involving smooth muscle cells |
| 01/22/2002 | CA2051460C Pharmaceutical compounds |
| 01/22/2002 | CA1341333C Amylin peptides and uses thereof |
| 01/17/2002 | WO2002004641A1 Novel g protein-coupled receptor protein and dna thereof |
| 01/17/2002 | WO2002004640A1 Novel g protein-coupled receptor protein and dna thereof |
| 01/17/2002 | WO2002004639A1 Novel g protein-coupled receptor protein and dna thereof |
| 01/17/2002 | WO2002004636A1 NOVEL α-CATENIN EXPRESSED IN HEART AND TESTIS |
| 01/17/2002 | WO2002004624A1 Novel g protein-coupled receptor protein and dna thereof |
| 01/17/2002 | WO2002004623A2 ANTISENSE COMPOSITIONS TARGETED TO β1 ADRENOCEPTOR-SPECIFIC MRNA AND METHODS OF USE |
| 01/17/2002 | WO2002004612A2 Drug metabolizing enzymes |
| 01/17/2002 | WO2002004499A1 Chemokine receptor modulators, production and use |
| 01/17/2002 | WO2002004491A2 Methods and compositions relating to muscle selective calcineurin interacting protein (mcip) |
| 01/17/2002 | WO2002004490A2 Lipid metabolism molecules |
| 01/17/2002 | WO2002004475A1 9-substituted adenine derivatives as prodrug regulators of cell and tissue function |
| 01/17/2002 | WO2002004474A1 Adenosine compound and pharmaceutical composition containing the same |
| 01/17/2002 | WO2002004461A1 Hydropyridine derivative acid addition salts |
| 01/17/2002 | WO2002004446A1 New bispidine compounds and their use in the treatment of cardiac arrhythmias |
| 01/17/2002 | WO2002004438A1 Bifunctional agents possessing antioxidant and antiarrhythmic activity |
| 01/17/2002 | WO2002004434A1 Colchinol derivatives as vascular damaging agents |
| 01/17/2002 | WO2002004433A2 Melanin concentrating hormone receptor ligands |
| 01/17/2002 | WO2002004429A1 Pyrimidine derivatives |
| 01/17/2002 | WO2002004427A1 Phenylpyridazine derivatives and drugs containing the same |
| 01/17/2002 | WO2002004421A2 Pyridoxine and pyridoxal analogues: cardiovascular therapeutics |
| 01/17/2002 | WO2002004031A1 Compositions and methods for treating cardiovascular disorders |
| 01/17/2002 | WO2002004025A1 Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| 01/17/2002 | WO2002004015A1 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use |
| 01/17/2002 | WO2002004008A2 Methods of therapy with thrombin derived peptides |
| 01/17/2002 | WO2002003996A1 Use of dammarane-type tritepenoid saporins |
| 01/17/2002 | WO2002003993A2 Use of inhibitors to multidrug resistance protein 5 (mrp5) to enhance intracellular levels of cyclic nucleotides |
| 01/17/2002 | WO2002003991A2 Use of substituted indole compounds for increasing nitric oxide synthase activity |
| 01/17/2002 | WO2002003988A2 Use of substituted indole compounds for treating neuropeptide y-related conditions |
| 01/17/2002 | WO2002003977A2 Combinations of statins, estrogenic agents and optionally estrogens |
| 01/17/2002 | WO2002003972A2 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds |
| 01/17/2002 | WO2002003962A2 Drug delivery system for poorly water soluble drugs |
| 01/17/2002 | WO2002003918A2 Treating neural conditions resulting from spinal cord contusions and other causes |
| 01/17/2002 | WO2001068064A3 Use of cdp-choline for the prophylactic treatment of cerebral ischemia |
| 01/17/2002 | WO2001062726A3 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| 01/17/2002 | WO2001049249A3 Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
| 01/17/2002 | WO2001047922A3 Azaindoles |
| 01/17/2002 | WO2001043765A3 Method for localized administration of fibrinolytic metalloproteinases |
| 01/17/2002 | WO2001041775A3 Use of procyanidins in the maintenance of vascular health and modulation of the inflammatory response |
| 01/17/2002 | WO2001041703A3 Method for treating allergic diseases |
| 01/17/2002 | WO2001038878A3 Pin1 as a marker for abnormal cell growth |
| 01/17/2002 | WO2001038303A3 Vitamin d analogues |
| 01/17/2002 | WO2001032696A3 Traf family proteins |
| 01/17/2002 | WO2001027290A3 Aortic carboxypeptidase-like protein and nucleic acids encoding same |
| 01/17/2002 | WO2001021259A3 Use and compositions for treating platelet-related disorders using anagrelide |
| 01/17/2002 | WO2001012598A3 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 01/17/2002 | WO2001007471A3 Cell cycle and proliferation proteins |
| 01/17/2002 | WO2000078971A3 Atp binding cassette transporter protein abc1 popypeptides |
| 01/17/2002 | WO2000078953A3 Human transport proteins |
| 01/17/2002 | WO2000078952A3 Human rna metabolism proteins (rmep) |
| 01/17/2002 | WO2000071493A3 INHIBITORS OF FACTOR Xa |
| 01/17/2002 | US20020007074 Imidazole derivatives having affinity for alpha2 receptors |
| 01/17/2002 | US20020007070 For inhibiting loss of blood platelets; inhibiting formation of blood platelet aggregates, fibrin, thrombus, and embolus; anticoagulants embedded in devices for blood collection, circulation, storage (catheters, dialysis machines); stents |
| 01/17/2002 | US20020007065 Cyclopentanone dihydropyridine compounds useful as potassium channel openers |
| 01/17/2002 | US20020006957 Method for the synthesis of compounds of formula I and their uses thereof |
| 01/17/2002 | US20020006951 Solid-state form of celecoxib having enhanced bioavailability |
| 01/17/2002 | US20020006947 Aryl substituted pyrazoles, triazoles, and tetrazoles, and the use thereof |
| 01/17/2002 | US20020006946 Obesity, antidiabetic agents, cardiovascular disorders |
| 01/17/2002 | US20020006936 Anticancer agents; restenosis |
| 01/17/2002 | US20020006932 Central nervous system disorders; heeadaches, antiinflammatory agents |
| 01/17/2002 | US20020006929 Antiarrhythmia agent, antiproliferative agent |
| 01/17/2002 | US20020006927 Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses |
| 01/17/2002 | US20020006923 Thrombin inhibitors |
| 01/17/2002 | US20020006917 Method of locking 1alpha-OH of vitamin D compounds in axial orientation |
| 01/17/2002 | US20020006899 Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
| 01/17/2002 | US20020006640 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 01/17/2002 | US20020006391 Genetic engineering |
| 01/17/2002 | DE10033337A1 Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel Biphenylcarbonsäureamide, their preparation and their use as medicaments |
| 01/17/2002 | DE10031651A1 Extrakte aus Sophora-Arten, Verfahren zu ihrer Herstellung und Verwendung Extracts of Sophora species, processes for their preparation and use |
| 01/17/2002 | DE10031650A1 Verwendung von Extrakten aus Sophora flavescens oder Sophora subprostrata zur Prophylaxe und Therapie von Krankheitszuständen, die durch einen Mangel an Östrogenen oder durch andere hormonelle Dysregulationen verursacht werden The use of extracts from Sophora flavescens or Sophora subprostrata for the prophylaxis and treatment of pathological conditions caused by estrogen deficiency or by other hormonal dysregulation |
| 01/17/2002 | DE10031389A1 Pyrimidinderivate und ihre Verwendung zur Prophylaxe und Therapie der zerebralen Ischämie Pyrimidine derivatives and their use for the prophylaxis and therapy of cerebral ischemia |
| 01/17/2002 | DE10005302A1 Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives |
| 01/17/2002 | CA2416199A1 Adenosine compound and pharmaceutical composition containing the same |
| 01/17/2002 | CA2415967A1 Methods and compositions relating to muscle selective calcineurin interacting protein (mcip) |
| 01/17/2002 | CA2415778A1 Methods of therapy with thrombin derived peptides |
| 01/17/2002 | CA2415624A1 Compositions and methods for treating cardiovascular disorders |
| 01/17/2002 | CA2415523A1 Bifunctional agents possessing antioxidant and antiarrhythmic activity |
| 01/17/2002 | CA2415483A1 Antisense compositions targeted to .beta.1 adrenoceptor-specific mrna and methods of use |
| 01/17/2002 | CA2415081A1 Drug delivery system for poorly water soluble drugs |
| 01/17/2002 | CA2414387A1 Drug metabolizing enzymes |
| 01/17/2002 | CA2414219A1 Lipid metabolism molecules |
| 01/17/2002 | CA2414198A1 Melanin concentrating hormone receptor ligands |
| 01/17/2002 | CA2414188A1 Pyridoxine and pyridoxal analogues: cardiovascular therapeutics |
| 01/17/2002 | CA2414111A1 Use of substituted indole compounds for increasing nitric oxide synthase activity |
| 01/17/2002 | CA2414060A1 Combinations of statins, estrogenic agents and optionally estrogens |
| 01/17/2002 | CA2413042A1 Phenylpyridazine derivatives and drugs containing the same |
| 01/17/2002 | CA2412848A1 New bispidine compounds and their use in the treatment of cardiac arrhythmias |
| 01/17/2002 | CA2412162A1 Chemokine receptor modulators, production and use |
| 01/17/2002 | CA2412150A1 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use |
| 01/17/2002 | CA2411160A1 Colchinol derivatives as vascular damaging agents |